radiolabel

(redirected from radiolabeled)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

radiolabel

 [ra´de-o-la″b'l]
2. to incorporate such a radioactive label into a compound.

radiolabel

/ra·dio·la·bel/ (ra´de-o-la″b'l)
2. to incorporate such a radioactive label into a compound.

radiolabel

(rā′dē-ō-lā′bəl)
tr.v. radiola·beled, radiola·beling, radiola·bels or radiola·belled or radiola·belling
To tag (a hormone, enzyme, or other substance) with a radioactive tracer.
n.
A radioactive isotope used as a tracer; a radiotracer.
References in periodicals archive ?
Radiolabeled APIs manufactured under non-GMP conditions may be used in pre-clinical studies to evaluate the ADMET profile.
The high accumulation of the radiolabeled complex in liver is also concordant with findings already reported by Thomas et al [24].
The study demonstrates that radiolabeled dextran cysteamine mannose might prove a successful radiopharmaceutical for sentinel lymph node detection in future clinical applications.
Human placental microsomes (50 [micro]g protein) were incubated with radiolabeled androstenedione (100 pmol/tube) at 37[degrees]C for 15 min, in the presence or absence of various concentrations of Roundup or glyphosate in 1 mL total volume of 50 mM Tris-maleate buffer (pH 7.
The bacteria soon went to work "eating" the radiolabeled contaminants.
ASCO abstract re-confirms that intravenous radiolabeled TM601 can cross the blood-brain barrier and bind to tumor tissue-
In one method, the researchers bound the ATR to carbohydrate beads, added radiolabeled DNA, washed the beads three times to eliminate unbound DNA, and then visualized the ATR-bound DNA by autoradiograph.
The company had previously received Orphan designation for the radiolabeled version, 131I-TM601, which recently completed patient enrollment in a Phase 2 clinical trial in glioma and a Phase 1 trial in multiple tumor types.
The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer.
Onalta, which has been studied in several clinical trials in the United States, is a radiolabeled peptide that the company intends to develop for the treatment of metastatic pancreatic neuroendocrine and carcinoid tumors in patients whose symptoms are not controlled by somatostatin analogue therapy.
ZK-BA (Solazed[TM]) joins Azedra[TM] (Ultratrace[TM] iobenguane I 131) and Onalta[TM] (an yttrium-90 radiolabeled somatostatin peptide analog) in Molecular Insight's portfolio of targeted radiotherapeutic product candidates.
Azedra, developed using Molecular Insight's proprietary Ultratrace technology, is designed to maximize the delivery of radiolabeled MIBG molecules to targeted neuroendocrine tumors to effectively enable safe and effective diagnosis and treatment while minimizing the amount of non-radioactive MIBG molecules that are delivered to the patient.